Cel Sci (CVM) Gains from Investment Securities (2019 - 2020)
Cel Sci (CVM) posted Gains from Investment Securities of -$805753.0 for Q2 2020, down 119.76% sequentially from $4.1 million in Q3 2019.
Cel Sci (CVM) Gains from Investment Securities (2019 - 2020) Analysis & Trends
Cel Sci has reported Gains from Investment Securities for 2 years, with the latest figure at -$805753.0 in Q2 2020.
- Quarterly Gains from Investment Securities changed N/A year-over-year to -$805753.0 in Q2 2020, while the trailing twelve-month figure through Sep 2021 was -$805753.0 (changed N/A YoY) and the FY2020 annual result came in at $805753.0, up 5.94% from the prior year.
- Gains from Investment Securities eased to -$805753.0 in Q2 2020 per CVM's latest filing, from $4.1 million in the prior quarter.
- Over five years, Gains from Investment Securities peaked at $4.1 million in Q3 2019 and troughed at -$805753.0 in Q2 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Cel Sci | 2.12 Mn | -4.42 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2020 | -805,753.00 |
| Jun 30, 2020 | -805,753.00 |
| Sep 30, 2019 | 4.08 Mn |
| Sep 30, 2019 | 4.08 Mn |